Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779883 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
A Phase 1 study, sponsored by Memgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00779883 is a Phase 1 study that has completed, run by Memgen. The registered enrollment target is 9 participants.
The verdict
NCT00779883, a Phase 1 study, has completed, sponsored by Memgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients with chronic lymphocytic leukemia (CLL).
Interventions
- BIOLOGICAL ISF35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779883
The ClinicalTrials.gov registry entry for NCT00779883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memgen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISF35 is the first listed.
NCT00779883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779883 about?
NCT00779883 is a clinical study titled "A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)". The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients with chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT00779883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00779883?
The interventions under investigation include: ISF35 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00779883?
This trial is sponsored by Memgen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.